Abstract | BACKGROUND: METHODS: RESULTS: Twenty-three patients were identified. The patients were heavily pretreated with a median of 7 prior regimens including a median of 3 prior platinum regimens. The combination regimen included cyclophosphamide in 15 (65%), 5-fluorouracil (5-FU) in 6 (26%), docetaxel in 1 (4%), and gemcitibine/ liposomal doxorubicin in 1 (4%). Two (9%) women developed chylous ascites during treatment. CTC Grade 4-5 toxicities occurred in 4 (17%) subjects. Gastrointestinal perforation occurred in 2 (9%) patients. Measurable disease was present in 22. The overall best response rate was 35% and all 8 were partial responses (PRs). Stable disease was found in a further 10 (44%) women, whereas progressive disease was observed in 5 (22%). The median time to progression was 5.6 months in patients with a PR and 2.3 months in subjects with stable disease. Three (13%) women experienced a progression-free interval (PFI) of >6 months. At last follow-up, 8 (35%) subjects had died of disease, whereas 15 (65%) women were alive with disease. CONCLUSIONS: Combination bevacizumab therapy demonstrated activity in heavily pretreated women with ovarian cancer. Gastrointestinal perforations were identified in 9%. Despite the toxicity of the regimen, prospective studies, particularly in less heavily pretreated patients, are warranted.
|
Authors | Jason D Wright, Andrea Hagemann, Janet S Rader, Dana Viviano, Randall K Gibb, Lori Norris, David G Mutch, Matthew A Powell |
Journal | Cancer
(Cancer)
Vol. 107
Issue 1
Pg. 83-9
(Jul 01 2006)
ISSN: 0008-543X [Print] United States |
PMID | 16736514
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2006 American Cancer Society. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Platinum Compounds
- Taxoids
- Deoxycytidine
- Docetaxel
- Bevacizumab
- Doxorubicin
- Cyclophosphamide
- Fluorouracil
- Gemcitabine
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bevacizumab
- Cohort Studies
- Cyclophosphamide
(administration & dosage)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Docetaxel
- Doxorubicin
(administration & dosage)
- Drug Resistance, Neoplasm
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Intestinal Perforation
(chemically induced)
- Middle Aged
- Neoplasms, Glandular and Epithelial
(drug therapy)
- Ovarian Neoplasms
(drug therapy)
- Platinum Compounds
(administration & dosage)
- Retrospective Studies
- Taxoids
(administration & dosage)
- Tomography Scanners, X-Ray Computed
- Treatment Outcome
- Gemcitabine
|